Colorectal Adenocarcinoma Clinical Trial
Official title:
The Role of Multimodality Management in Risk-Stratified Patients With Lung-Limited Metastatic Colorectal Cancer
Verified date | January 2024 |
Source | M.D. Anderson Cancer Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This phase II trial studies how well chemotherapy and/or metastasectomy work in treating patients with colorectal adenocarcinoma that has spread to the lungs (metastases). Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Metastasectomy is a surgical procedure that removes tumors formed from cells that have spread from other places in the body. It is not yet known if chemotherapy and metastasectomy together works better in treating patients with metastatic colorectal adenocarcinoma with lung metastases.
Status | Active, not recruiting |
Enrollment | 40 |
Est. completion date | January 31, 2030 |
Est. primary completion date | January 31, 2030 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Histological confirmation of colorectal adenocarcinoma - Metastatic colorectal cancer involving the lung classified as determined by the treating clinical team - Diagnosis of colorectal metastasis to lung made either histologically with trans-thoracic needle biopsy or clinically based on radiographic imaging - Identification as a medically appropriate candidate for surgical resection of the lung metastasis (metastases) according to the evaluating cardiothoracic surgeon. Standard justification for deeming a patient medically operable based on: - Pulmonary reserve adequate to tolerate complete resection of all intrathoracic disease, as deemed by thoracic surgeon, which may be determined by: - Baseline forced expiratory volume in one second (FEV1) > 40% predicted - Post-operative predicted FEV1 > 30% predicted - Diffusion capacity of the lung for carbon monoxide (DLCO) > 40% predicted - Absent baseline hypoxemia and/or hypercapnia - Exercise oxygen consumption > 50% predicted - Absent severe pulmonary hypertension - Absent severe cerebral, cardiac, or peripheral vascular disease - Absent severe chronic heart disease - Ability to tolerate surgical resection and acceptable operative risk as deemed by thoracic surgeon based on performance status and medical comorbidities - Identification as a medically appropriate candidate for systemic chemotherapy at the discretion of the evaluating medical oncologist - Resection/definitive therapy of primary colorectal tumor with no suspicion of recurrence. Prior radiation to a rectal adenocarcinoma is permitted - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 - Ability to provide informed consent for participation - Leukocytes >= 2,000/mcL - Absolute neutrophil count >= 1,000/mcL - Hemoglobin >= 9.0 gm/dL - Platelet count >= 100,000/mcL - Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (except patients with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL) - Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x ULN - Serum creatinine =< 1.5 x ULN OR creatinine clearance (CrCl >= 50 mL/min (if using the Cockcroft-Gault formula) - Patients (men and women) of child bearing potential should use an effective (for them) method of birth control throughout their participation in this study Exclusion Criteria: - Tumor involvement at other metastatic sites (e.g., liver, distant lymph nodes) that has not been definitively treated. Prior surgical resection for metastatic disease at other (non-pulmonary) sites is permitted - Presence of intact primary colorectal adenocarcinoma (or of an anastomotic recurrence) - Previous radiotherapy to a lung metastasis that is still detectable radiographically - Known dihydropyrimidine dehydrogenase (DPD) deficiency that would preclude the patient from tolerating 5- fluorouracil chemotherapy - Prior intolerance of systemic therapies used as standard regimens in the treatment of metastatic CRC that would prohibit further receipt of systemic chemotherapy and/or biologic agents -e.g.,5-fluorouracil, oxaliplatin, irinotecan, anti-VEGF therapies (e.g., bevacizumab, ramucirumab), or anti-EGFR therapies (e.g., cetuximab, panitumumab, for patients with RAS wild-type colorectal tumors) - Prior therapy with regorafenib or trifluridine/tipiracil (TAS-102) for metastatic/unresectable colorectal cancer - Synchronous primary or prior malignancy in the past 5 years other than non-melanomatous skin cancer or in situ cancer - Pregnant or lactating women, as treatment involves unforeseeable risks to the embryo or fetus |
Country | Name | City | State |
---|---|---|---|
Canada | University of Montreal | Montreal | Quebec |
Canada | University Health Network Princess Margaret Cancer Center P2C | Toronto | Ontario |
United States | Baylor Colllege of Medicine | Houston | Texas |
United States | M D Anderson Cancer Center | Houston | Texas |
United States | Thomas Jefferson University | Philadelphia | Pennsylvania |
United States | Washington University School of Medicine | Saint Louis | Missouri |
Lead Sponsor | Collaborator |
---|---|
M.D. Anderson Cancer Center | National Cancer Institute (NCI) |
United States, Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Recurrence-free survival (Low risk) | The primary objective for the low risk group is to evaluate the efficacy of chemotherapy plus surgical resection versus surgical resection alone measured by recurrence-free survival (RFS). The event includes recurrence and death due to any cause. Patients will be stratified at randomization according to three variables: age (age >= 60 years vs age < 60 years), RAS mutation status (mutant vs wild type), and location of primary tumor within colon/rectum (right/cecum/ascending colon/hepatic flexure/transverse colon vs left/distal to transverse colon). | Up to 2 years | |
Primary | Overall survival (High risk) | The primary objective for the high-risk group is to evaluate the efficacy of chemotherapy plus surgical resection versus chemotherapy alone measured by overall survival (OS). The event includes death due to any cause. Patients will be stratified at randomization according to 4 variables: response to chemotherapy in the preceding three months of treatment (complete or partial response vs stable disease by Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 criteria), RAS mutated vs RAS wild type tumors, right versus left-sided primary tumors, and oxaliplatin-based vs irinotecan-based chemotherapy in the initial treatment period on study. | Up to 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04094688 -
Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer
|
Phase 3 | |
Active, not recruiting |
NCT04474470 -
A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT06050447 -
Factors Affecting the Results of Treatment of Patients With Colorectal Cancer
|
||
Recruiting |
NCT05504252 -
METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin
|
Phase 2 | |
Suspended |
NCT04108481 -
Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT00597506 -
Expanded Cohort for Metastatic Colorectal Cancer (MCRC) Using Bevacizumab + Everolimus
|
Phase 2 | |
Recruiting |
NCT05902988 -
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT05477836 -
Feasibility and Safety of MiWEndo-assisted Colonoscopy
|
N/A | |
Recruiting |
NCT05620134 -
Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT03715933 -
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
|
Phase 1 | |
Recruiting |
NCT04870879 -
Colorectal Metastasis and Liver Transplantation With Organs From Deceased Donors
|
N/A | |
Recruiting |
NCT04773769 -
Study of Guanábana Leaves for The Treatment of Patients With Gastric, Gastroesophageal Junction, Pancreatic and Colorectal Adenocarcinomas; Hepatocellular Carcinoma, and Low Grade Lymphomas
|
N/A | |
Recruiting |
NCT04739072 -
Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study
|
||
Recruiting |
NCT06134440 -
ImmunoNutrition and Colorectal Adenocarcinoma Surgery - INCAS Study
|
N/A | |
Withdrawn |
NCT03708536 -
Bevacizumab Plus Capecitabin vs S-1 as Maintenance Treatment Following First-line Chemotherapy in the Patients With Advanced Colorectal Adenocarcinoma
|
Phase 3 | |
Withdrawn |
NCT02413853 -
Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer
|
Phase 2 | |
Completed |
NCT00165217 -
Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma
|
Phase 2 | |
Active, not recruiting |
NCT04457284 -
Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer
|
Phase 2 | |
Suspended |
NCT04111172 -
A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma
|
Phase 2 | |
Not yet recruiting |
NCT06118658 -
Chemotherapy Sequential Tislelizumab After Radical Resection in Patients With dMMR/MSI-H or POLE/POLD1 Mutations
|
Phase 2 |